Anna Giczewska, Krzysztof Pastuszak, Megan Houweling, U Kulsoom Abdul, Noa Faaij, Laurine Wedekind, David Noske, Thomas Wurdinger, Anna Supernat, Bart A Westerman
{"title":"利用卷积神经网络图像解码胶质母细胞瘤单球体培养物的纵向药物协同作用评估","authors":"Anna Giczewska, Krzysztof Pastuszak, Megan Houweling, U Kulsoom Abdul, Noa Faaij, Laurine Wedekind, David Noske, Thomas Wurdinger, Anna Supernat, Bart A Westerman","doi":"10.1093/noajnl/vdad134","DOIUrl":null,"url":null,"abstract":"Abstract Background In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the interaction between drugs over time is critical for predicting drug combination effectiveness and minimizing the risk of therapy resistance. However, as viability readouts of drug combination experiments are commonly performed as an endpoint where cells are lysed, longitudinal drug-interaction monitoring is currently only possible through combined endpoint assays. Methods We provide a method for massive parallel monitoring of drug interactions for 16 drug combinations in three glioblastoma models over a time frame of 18 days. In our assay, viabilities of single neurospheres are to be estimated based on image information taken at different time points. Neurosphere images taken at the final day (day 18) were matched to the respective viability measured by CellTiter-Glo 3D at the same day. This allowed to use machine learning to decode image information to viability values at day 18 as well as for the earlier time points (at day 8, 11, 15). Results Our study shows that neurosphere images allow to predict cell viability from extrapolated viabilities. This enables to assess the drug interactions in a time-window of 18 days. Our results show a clear and persistent synergistic interaction for several drug combinations over time. Conclusions Our method facilitates longitudinal drug-interaction assessment, providing new insights into the temporal-dynamic effects of drug combinations in 3D neurospheres which can help to identify more effective therapies against glioblastoma.","PeriodicalId":94157,"journal":{"name":"Neuro-oncology advances","volume":"14 3","pages":"0"},"PeriodicalIF":3.7000,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures\",\"authors\":\"Anna Giczewska, Krzysztof Pastuszak, Megan Houweling, U Kulsoom Abdul, Noa Faaij, Laurine Wedekind, David Noske, Thomas Wurdinger, Anna Supernat, Bart A Westerman\",\"doi\":\"10.1093/noajnl/vdad134\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Background In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the interaction between drugs over time is critical for predicting drug combination effectiveness and minimizing the risk of therapy resistance. However, as viability readouts of drug combination experiments are commonly performed as an endpoint where cells are lysed, longitudinal drug-interaction monitoring is currently only possible through combined endpoint assays. Methods We provide a method for massive parallel monitoring of drug interactions for 16 drug combinations in three glioblastoma models over a time frame of 18 days. In our assay, viabilities of single neurospheres are to be estimated based on image information taken at different time points. Neurosphere images taken at the final day (day 18) were matched to the respective viability measured by CellTiter-Glo 3D at the same day. This allowed to use machine learning to decode image information to viability values at day 18 as well as for the earlier time points (at day 8, 11, 15). Results Our study shows that neurosphere images allow to predict cell viability from extrapolated viabilities. This enables to assess the drug interactions in a time-window of 18 days. Our results show a clear and persistent synergistic interaction for several drug combinations over time. Conclusions Our method facilitates longitudinal drug-interaction assessment, providing new insights into the temporal-dynamic effects of drug combinations in 3D neurospheres which can help to identify more effective therapies against glioblastoma.\",\"PeriodicalId\":94157,\"journal\":{\"name\":\"Neuro-oncology advances\",\"volume\":\"14 3\",\"pages\":\"0\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2023-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neuro-oncology advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/noajnl/vdad134\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/noajnl/vdad134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Longitudinal drug synergy assessment using convolutional neural network image-decoding of glioblastoma single-spheroid cultures
Abstract Background In recent years, drug combinations have become increasingly popular to improve therapeutic outcomes in various diseases, including difficult to cure cancers such as the brain cancer glioblastoma. Assessing the interaction between drugs over time is critical for predicting drug combination effectiveness and minimizing the risk of therapy resistance. However, as viability readouts of drug combination experiments are commonly performed as an endpoint where cells are lysed, longitudinal drug-interaction monitoring is currently only possible through combined endpoint assays. Methods We provide a method for massive parallel monitoring of drug interactions for 16 drug combinations in three glioblastoma models over a time frame of 18 days. In our assay, viabilities of single neurospheres are to be estimated based on image information taken at different time points. Neurosphere images taken at the final day (day 18) were matched to the respective viability measured by CellTiter-Glo 3D at the same day. This allowed to use machine learning to decode image information to viability values at day 18 as well as for the earlier time points (at day 8, 11, 15). Results Our study shows that neurosphere images allow to predict cell viability from extrapolated viabilities. This enables to assess the drug interactions in a time-window of 18 days. Our results show a clear and persistent synergistic interaction for several drug combinations over time. Conclusions Our method facilitates longitudinal drug-interaction assessment, providing new insights into the temporal-dynamic effects of drug combinations in 3D neurospheres which can help to identify more effective therapies against glioblastoma.